Synapse - Works

Results (2969)

Phase 1 dose-escalation study of the heat shock protein 90 inhibitor BIIB021 with trastuzumab in HER2+ metastatic breast cancer

Meeting Abstract

Modi, S.; Ismail-Khan, R.; Munster, P.; Lucas, M.; Galluppi, G. R.; Tangri, S.; Chen, Y.; Yamashita, M.; Storgard, C. M.; Moulder, S.
Cancer Research (2010)

Fulltext@MSK | Save

A dose-escalation study of trastuzumab-DM1 (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive, locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen

Meeting Abstract

Krop, I. E.; Modi, S.; Elias, A.; LoRusso, P.; Choi, Y. J.; Lu, M.
Cancer Research (2010)

Fulltext@MSK | Save

Late toxicity and patient self-assessment of breast appearance/satisfaction on RTOG 0319: A phase II trial of three dimensional conformal radiation therapy (3DCRT) partial breast irradiation (PBI) following lumpectomy for stage I and II breast cancer

Meeting Abstract

Chafe, S. J.; Moughan, J.; Vicini, F. A.; Wong, J. W. C.; Pass, H. A.; Rabinovich, R. A.; Arthur, D. W.; Petersen, I. A.; White, J. R.; McCormick, B.
Cancer Research (2010)

Fulltext@MSK | Save

Symptomatic congestive heart failure after neo/adjuvant dose-dense epirubicin: A retrospective analysis of two trials with long-term follow-up

Meeting Abstract

Gajria, D.; Pokuri, V.; Steingart, R.; Hudis, C.; Dang, C.
Cancer Research (2010)

Fulltext@MSK | Save

Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions: Analysis of fresh frozen tissue using SNP array

Meeting Abstract

Andrade, V. P.; Morrogh, M.; Giri, D.; Ostrovnaya, I.; Seshan, V.; Olvera, N.; Begg, C.; Morrow, M.; King, T. A.
Cancer Research (2010)

Fulltext@MSK | Save

PI3K mutations are more common in low grade DCIS

Meeting Abstract

Sakr, R.; Chandarlapaty, S.; Andrade, V.; Giri, D.; Muhsen, S.; Paik, W.; Morrow, M.; Rosen, N.; King, T.
Cancer Research (2010)

Fulltext@MSK | Save

Pharmacokinetics (PK) of trastuzumab-DM1 (T-DM1) and paclitaxel (T) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen

Meeting Abstract

Lu, D.; Krop, I.; Modi, S.; Elias, A.; LoRusso, P.; Huang, J.; Lu, M.; Girish, S.
Cancer Research (2010)

Fulltext@MSK | Save

Adherence, persistence and toxicity with oral CMF in older women with early stage breast cancer in CALGB 49907 (Adherence companion study 60104)

Meeting Abstract

Ruddy, K. J.; Archer, L. E.; Cohen, H. J.; Winer, E. P.; Hudis, C. A.; Muss, H. B.; Partridge, A. H.
Cancer Research (2010)

Fulltext@MSK | Save

A novel capecitabine schedule (7 on—7 off) is feasible with lapatinib for patients with HER2-positive metastatic breast cancer refractory to trastuzumab

Meeting Abstract

Gajria, D.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Drullinsky, P.; D'Andrea, G.; Lake, D.; Norton, L.; Hudis, C.; more...
Cancer Research (2010)

Fulltext@MSK | Save

A Phase 3 randomized, controlled trial of myocet, trastuzumab and paclitaxel vs. trastuzumab and paclitaxel for 1st line therapy of HER2+ metastatic breast cancer

Meeting Abstract

Baselga, J.; Manikhas, A.; Roman, L.; Semiglazov, V.; Goldfarb, R. H.; Forenza, S.; Matera, J.; Azarnia, N.; Hudis, C.; Rozencweig, M.
Cancer Research (2010)

Fulltext@MSK | Save